B7-33

Cardiometabolic / Anti-fibrotic

Anti-fibrotic and cardio-renal protection positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: Relaxin receptor RXFP1 biased agonism
Primary market use: Cardio-renal

Pharmacology

Molecular weight (Da): ~3900
Oral bioavailability: N/A
Half-life: ~5–60 min parent peptide; analogs may be longer
Route tags: Route-dependent / verify
Evidence level: Preclinical
Clinical status: Experimental
Value-for-money score: 4 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Potential remodeling via fibrosis reduction

Sources

https://pubmed.ncbi.nlm.nih.gov/